Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XmAb22841 · 1 trial · 23 indications
Rates of treatment-related adverse events (AEs), graded by CTCAE v4.03, and additionally categorized as either immune-related or non-immune AEs.
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | Arm 1: XmAb®22841 Monotherapy |
| Arm 2 | EXPERIMENTAL | Arm 2: Combination of XmAb®22841 and Pembrolizumab (Keytruda®) |
| Name | Type | Description |
|---|---|---|
| XmAb®22841 | BIOLOGICAL | Monoclonal bispecific antibody |
| Pembrolizumab (Keytruda®) | BIOLOGICAL | FDA-approved humanized monoclonal antibody |
Inclusion Criteria: PART A (Dose Escalation Cohorts) 1. All subjects' cancer must have progressed after treatment with all available therapies that are known to confer clinical benefit, or are intolerant to treatment, or refuse standard treatment. 2. All subjects must have adequate archival tumor,...
Top 20 of 51 competitors
XmAb22841 is an investigational monoclonal antibody being studied for the treatment of melanoma and other advanced solid tumors. It is being evaluated as a monotherapy and in combination with pembrolizumab in patients with selected advanced solid tumors, including melanoma, cervical carcinoma, pancreatic carcinoma, and others.
XmAb22841 is a monoclonal antibody that targets CTLA-4, an immune checkpoint protein that suppresses T-cell activation. By binding to CTLA-4, XmAb22841 is designed to enhance the immune system's anti-tumor response. It is being studied in combination with pembrolizumab, which targets PD-1.
XmAb22841 is being developed by Xencor, Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol XNCR. Xencor is conducting clinical trials to evaluate the safety and efficacy of XmAb22841 in patients with advanced solid tumors.
XmAb22841 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. A Phase 1 study of XmAb22841 as monotherapy and in combination with pembrolizumab has been completed in patients with selected advanced solid tumors.
XmAb22841 has been studied in one clinical trial, NCT03849469, which is a Phase 1 study of XmAb22841 monotherapy and in combination with pembrolizumab in subjects with selected advanced solid tumors. The trial enrolled 78 participants and has been completed.
No, XmAb22841 is not the same as pembrolizumab. XmAb22841 is an investigational monoclonal antibody targeting CTLA-4, while pembrolizumab is an approved PD-1 inhibitor. In the clinical trial, XmAb22841 was studied both alone and in combination with pembrolizumab.